Difference between revisions of "Melanoma - historical"
m |
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 50%; text-align:center;"" to "{| class="wikitable" style="width: 40%; text-align:center;"") |
||
Line 47: | Line 47: | ||
BCG & DTIC: '''<u>B</u>'''acillus '''<u>C</u>'''almette-'''<u>G</u>'''uérin & '''<u>D</u>'''imethyl '''<u>T</u>'''riazeno '''<u>I</u>'''midazole '''<u>C</u>'''arboxamide (Dacarbazine) | BCG & DTIC: '''<u>B</u>'''acillus '''<u>C</u>'''almette-'''<u>G</u>'''uérin & '''<u>D</u>'''imethyl '''<u>T</u>'''riazeno '''<u>I</u>'''midazole '''<u>C</u>'''arboxamide (Dacarbazine) | ||
===Regimen {{#subobject:523c9c|Variant=1}}=== | ===Regimen {{#subobject:523c9c|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable" style="width: 40%; text-align:center;" |
!style="width: 25%"|Study | !style="width: 25%"|Study | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] |
Revision as of 02:30, 1 July 2021
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main melanoma page for current regimens.
20 regimens on this page
34 variants on this page
|
Adjuvant thereapy
Bevacizumab monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Corrie et al. 2014 (AVAST-M) | 2007-2012 | Phase III (E-esc) | Observation | Did not meet primary endpoint of OS1 (HR 0.98, 95% CI 0.82-1.16) |
Preceding treatment
Targeted therapy
- Bevacizumab (Avastin) 7.5 mg/kg IV once on day 1
21-day cycle for 18 cycles (1 year)
References
- AVAST-M: Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Young G, Lorigan P. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncol. 2014 May;15(6):620-30. Epub 2014 Apr 15. Erratum in: Lancet Oncol. 2014 Aug;15(9):e365. Lancet Oncol. 2014 Jun;15(7):e253. link to original article PubMed ISRCTN81261306
- Update: Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR; AVAST-M Investigators, Nathan P, Lorigan P, Dziewulski P, Holikova S, Panwar U, Tahir S, Faust G, Thomas A, Corrie P, Sirohi B, Kelly C, Middleton M, Marples M, Danson S, Lester J, Marshall E, Ajaz M, Houston S, Board R, Eaton D, Waterston A, Nobes J, Loo S, Gray G, Stubbings H, Gore M, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Marsden J, Westwell S, Casasola R, Chao D, Maraveyas A, Marshall E, Patel P, Ottensmeier C, Farrugia D, Humphreys A, Eccles B, Dega R, Herbert C, Price C, Brunt M, Scott-Brown M, Hamilton J, Hayward RL, Smyth J, Woodings P, Nayak N, Burrows L, Wolstenholme V, Wagstaff J, Nicolson M, Wilson A, Barlow C, Scrase C, Podd T, Gonzalez M, Stewart J, Highley M, Wolstenholme V, Grumett S, Goodman A, Talbot T, Nathan K, Coltart R, Gee B, Gore M, Farrugia D, Martin-Clavijo A, Marsden J, Price C, Farrugia D, Nathan K, Coltart R, Nathan K, Coltart R. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Ann Oncol. 2018 Aug 1;29(8):1843-1852. Erratum in: Ann Oncol. 2019 Dec 1;30(12):2013-2014. Erratum in: Ann Oncol. 2019 Dec;30(12):2013-2014. link to original article link to PMC article PubMed
Metastatic or unresectable disease
BCG & Dacarbazine
back to top |
BCG & DTIC: Bacillus Calmette-Guérin & Dimethyl Triazeno Imidazole Carboxamide (Dacarbazine)
Regimen
Study | Evidence |
---|---|
Gutterman et al. 1974 | Non-randomized |
Immunotherapy
Chemotherapy
References
- Gutterman JU, Mavligit G, Gottlieb JA, Burgess MA, McBride CE, Einhorn L, Freireich EJ, Hersh EM. Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and Bacillus Calmette--Guérin. N Engl J Med. 1974 Sep 19;291(12):592-7. link to original article PubMed
BHD
back to top |
BHD: BCNU (Carmustine), Hydroxyurea, Dacarbazine
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Costanzi et al. 1984 (SWOG S7727) | NR | Phase III (C) | 1. BHD & Levamisole 2. DTIC & Dactinomycin |
Seems not superior |
Chemotherapy
References
- SWOG S7727: Costanzi JJ, Fletcher WS, Balcerzak SP, Taylor S, Eyre HJ, O'Bryan RM, Al-Sarraf M, Frank J. Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma: a Southwest Oncology Group study. Cancer. 1984 Feb 15;53(4):833-6. link to original article PubMed
BVD
back to top |
BVD: BCNU (Carmustine), Vincristine, Dacarbazine
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Jelić et al. 2002 | NR | Phase III (C) | 1. BVD; high-dose 2. Bleomycin, Cisplatin, Vindesine 3. Carmustine & Procarbazine |
Seems not superior |
Chemotherapy
References
- Jelić S, Babovic N, Kovcin V, Milicevic N, Milanovic N, Popov I, Radosavljevic D. Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study. Melanoma Res. 2002 Feb;12(1):91-8. link to original article PubMed
Carboplatin & Dacarbazine
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Agarwala et al. 1999 | NR | Phase III (C) | Carboplatin, Dacarbazine, Tamoxifen | Did not meet primary endpoint of ORR |
Chemotherapy
- Carboplatin (Paraplatin) 300 mg/m2 IV once on day 1
- Dacarbazine (DTIC) 1000 mg/m2 IV once on day 1
28-day cycle for at least 2 cycles
References
- Agarwala SS, Ferri W, Gooding W, Kirkwood JM. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer. 1999 May 1;85(9):1979-84. link to original article contains protocol PubMed
CDB
back to top |
CDB: Cisplatin, Dacarbazine, BCNU (Carmustine)
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Creagan et al. 1999 | 1991-1996 | Phase III (C) | CDB & Tamoxifen | Seems not superior |
Rusthoven et al. 1996 | 1992-1995 | Phase III (E-de-esc) | CDB & Tamoxifen | Seems not superior |
Ridolfi et al. 2002 | 1997-1999 | Phase III (C) | Cisplatin, Dacarbazine, IL-2, IFN alfa-2b +/- Carmustine | Seems not superior |
Chemotherapy
References
- Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HK, Verma S, Armitage GR, Zee B, Bennett K; National Cancer Institute of Canada Clinical Trials Group. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol. 1996 Jul;14(7):2083-90. link to original article PubMed
- Creagan ET, Suman VJ, Dalton RJ, Pitot HC, Long HJ, Veeder MH, Vukov AM, Rowland KM, Krook JE, Michalak JC. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol. 1999 Jun;17(6):1884-90. link to original article PubMed
- Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O; Italian Melanoma Intergroup. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol. 2002 Mar 15;20(6):1600-7. link to original article contains verified protocol PubMed
Cisplatin, Dacarbazine, Interferon alfa-2b
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Keilholz et al. 2005 (EORTC 18951) | 1995-2000 | Phase III (C) | Cisplatin, Dacarbazine, IFN, IL-2 | Seems not superior |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Chemotherapy
Immunotherapy
28-day cycle for up to 4 cycles
References
- EORTC 18951: Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2005 Sep 20;23(27):6747-55. link to original article PubMed
Cisplatin, Dacarbazine, Tamoxifen
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Rosenberg et al. 1999 | 1993-1997 | Phase III (C) | Cisplatin, Dacarbazine, Tamoxifen, then IFN & IL-2 | Seems not superior |
Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.
Chemotherapy
Endocrine therapy
References
- Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol. 1999 Mar;17(3):968-75. link to original article PubMed
Dacarbazine & Tamoxifen
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cocconi et al. 1992 | 1983-1988 | Phase III (E-esc) | Dacarbazine | Seems to have superior OS |
Chemotherapy
Endocrine therapy
References
- Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, Buzzi F, Ceci G, Corgna E, Costa P, Lottici R, Papadia F, Sofra MC, Bacchi M. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med. 1992 Aug 20;327(8):516-23. link to original article PubMed